0000899243-19-017419.txt : 20190619 0000899243-19-017419.hdr.sgml : 20190619 20190619161522 ACCESSION NUMBER: 0000899243-19-017419 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20190617 FILED AS OF DATE: 20190619 DATE AS OF CHANGE: 20190619 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Ragan Paula CENTRAL INDEX KEY: 0001769914 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38295 FILM NUMBER: 19906206 MAIL ADDRESS: STREET 1: C/O X4 PHARMACEUTICALS, INC. STREET 2: 955 MASSACHUSETTS AVE., 4TH FLOOR CITY: CAMBRIDGE STATE: MA ZIP: 02139 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: X4 Pharmaceuticals, Inc CENTRAL INDEX KEY: 0001501697 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 273181608 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 955 MASSACHUSETTS AVENUE STREET 2: 4TH FLOOR CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 857-529-8300 MAIL ADDRESS: STREET 1: 955 MASSACHUSETTS AVENUE STREET 2: 4TH FLOOR CITY: CAMBRIDGE STATE: MA ZIP: 02139 FORMER COMPANY: FORMER CONFORMED NAME: Arsanis, Inc. DATE OF NAME CHANGE: 20100920 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2019-06-17 0 0001501697 X4 Pharmaceuticals, Inc XFOR 0001769914 Ragan Paula C/O X4 PHARMACEUTICALS, INC. 955 MASSACHUSETTS AVENUE, 4TH FLOOR CAMBRIDGE MA 02139 1 1 0 0 President and CEO Common Stock 2019-06-17 4 A 0 55928 0.00 A 237294 D Stock Option (right to buy) 14.75 2019-06-17 4 A 0 83893 0.00 A 2029-06-17 Common Stock 83893 83893 D Grant of restricted stock units to the Reporting Person under the Issuer's 2017 Equity Incentive Plan, with each restricted stock unit representing the contingent right to receive one share of common stock on the applicable vesting date. No amount was paid upon grant of the units. The restricted stock units vest in four equal annual installments on May 31, 2020, May 31, 2021, May 31, 2022 and May 31, 2023, subject to the Reporting Person continuing to provide services through each such date. Of the shares of common stock reported, 55,928 shares represent unvested restricted stock units. 25% of the shares subject to the option shall vest on June 17, 2020, with the remainder vesting in equal installments of 2.0833% of the shares subject to the option on the last day of each successive month thereafter for a period of 36 months, subject to the Reporting Person continuing to provide services through each such date. /s/ Adam S. Mostafa, attorney-in-fact 2019-06-19